Pioneering Venture Aims to Transform Treatment Beyond Cardiac Applications with Pulsed Field Ablation
MINNEAPOLIS, MN – September 4, 2025 – A significant development in the field of advanced medical technology has been announced with the launch of Del Medtech, a new company founded by renowned interventional cardiologist Steven Mickelsen, MD. This innovative venture is poised to expand the therapeutic reach of Pulsed Field Ablation (PFA) beyond its current primary application in treating cardiac arrhythmias, opening doors to novel treatment possibilities for a wider range of medical conditions.
Del Medtech’s mission centers on leveraging the unique advantages of PFA technology. PFA is a groundbreaking ablation modality that utilizes brief electrical pulses to selectively destroy unwanted tissue while leaving surrounding healthy structures unharmed. This highly targeted approach has demonstrated considerable promise in cardiac procedures, offering a safer and more precise alternative to traditional thermal ablation methods, which rely on heat or cold to eliminate tissue.
Dr. Mickelsen, a distinguished physician-scientist with a deep understanding of electrophysiology and innovative medical device development, is leading Del Medtech with a vision to unlock the full potential of PFA. The company’s focus will be on exploring and developing PFA-based solutions for non-cardiac indications, where the precise and non-thermal nature of the technology could offer significant clinical benefits.
While specific details of the non-cardiac applications Del Medtech will initially target have not yet been fully disclosed, the implications are vast. Conditions that currently rely on more invasive or less precise treatments could potentially be addressed with PFA’s refined capabilities. This could include a spectrum of diseases where targeted tissue ablation is a critical component of therapy.
The establishment of Del Medtech signifies a commitment to rigorous research, development, and clinical translation of PFA technology. By focusing on expanding its applications, the company aims to address unmet clinical needs and improve patient outcomes across various medical disciplines. Dr. Mickelsen’s leadership is expected to drive innovation and collaboration with healthcare professionals and researchers worldwide.
“We are at an exciting inflection point in medical technology,” stated Dr. Mickelsen. “Pulsed Field Ablation has already proven its value in cardiology, and we believe its fundamental principles of selective tissue destruction can be adapted to address a multitude of challenges in other areas of medicine. Del Medtech is dedicated to realizing this potential, bringing innovative PFA solutions to patients who could benefit from more precise and less invasive treatment options.”
The launch of Del Medtech underscores a growing recognition of PFA’s versatility and its capacity to revolutionize therapeutic approaches. As the company embarks on its mission, the medical community will be keenly watching its progress as it strives to expand the horizons of Pulsed Field Ablation, potentially ushering in a new era of patient care.
Steven Mickelsen, MD, Launches Del Medtech to Expand Pulsed Field Ablation Beyond the Heart
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
www.prnewswire.com published ‘Steven Mickelsen, MD, Launches Del Medtech to Expand Pulsed Field Ablation Beyond the Heart’ at 2025-09-04 18:14. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.